Common Contracts
3 similar Stock Purchase Agreement contracts by Juno Therapeutics, Inc.
EX-10.29 13 d772541dex1029.htm EXCLUSIVE LICENSE AGREEMENT EXECUTION VERSION [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH...Stock Purchase Agreement • May 5th, 2020 • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of December 3, 2014 (the “Execution Date”), between Juno Therapeutics, Inc., a Delaware corporation (“Juno”), having a place of business at 307 Westlake Ave. N, Suite 300, Seattle, Washington 98109, and Opus Bio, Inc., a Delaware corporation (“Opus”), having a place of business at 537 Steamboat Road, Suite 200, Greenwich, CT 06830.
EX-10.29 13 d772541dex1029.htm EXCLUSIVE LICENSE AGREEMENT EXECUTION VERSION [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH...Stock Purchase Agreement • May 5th, 2020 • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of December 3, 2014 (the “Execution Date”), between Juno Therapeutics, Inc., a Delaware corporation (“Juno”), having a place of business at 307 Westlake Ave. N, Suite 300, Seattle, Washington 98109, and Opus Bio, Inc., a Delaware corporation (“Opus”), having a place of business at 537 Steamboat Road, Suite 200, Greenwich, CT 06830.
EXCLUSIVE LICENSE AGREEMENTStock Purchase Agreement • December 9th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
